Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.
Nov. 6 Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly and make treatments more accessible, President Donald Trump announced Thursday.
The president said it will include pill versions of the drugs, which are to be made available soon, according to CNBC.
Medicare will begin to provide coverage for the obesity drugs for some people in mid-2026, which also might cause more private insurers to likewise add coverage for them.
The Trump administration in January also is launching the TrumpRx.gov website, which will enable consumers to access the GLP-1 drug discounts.
Novo’s Wegovy and Eli Lilly’s Zepbound obesity drugs, both of which are injectable, would cost $350 per month via TrumpRX.
Trump said those drugs have not been available as a weight-loss treatment through Medicare and „they’ve only rarely been covered by Medicaid“, as quoted by CNBC.
